NasdaqCM:ZSAN

Stock Analysis Report

Executive Summary

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology.

Snowflake

Fundamentals

Adequate balance sheet and overvalued.


Similar Companies

Share Price & News

How has Zosano Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

15.1%

ZSAN

1.7%

US Medical Equipment

2.3%

US Market


1 Year Return

-52.5%

ZSAN

10.1%

US Medical Equipment

5.6%

US Market

Return vs Industry: ZSAN underperformed the US Medical Equipment industry which returned 10.1% over the past year.

Return vs Market: ZSAN underperformed the US Market which returned 5.6% over the past year.


Shareholder returns

ZSANIndustryMarket
7 Day15.1%1.7%2.3%
30 Day-4.5%-1.7%-1.0%
90 Day-41.0%-1.7%-0.7%
1 Year-52.5%-52.5%11.0%10.1%7.9%5.6%
3 Year-85.5%-85.5%70.4%65.2%45.6%36.3%
5 Yearn/a128.5%103.2%65.8%47.6%

Price Volatility Vs. Market

How volatile is Zosano Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zosano Pharma undervalued compared to its fair value and its price relative to the market?

1.78x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate ZSAN's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate ZSAN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: ZSAN is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: ZSAN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate ZSAN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ZSAN is good value based on its PB Ratio (1.8x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is Zosano Pharma forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

8.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ZSAN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ZSAN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ZSAN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if ZSAN's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if ZSAN's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

High Future ROE: Insufficient data to determine if ZSAN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Zosano Pharma performed over the past 5 years?

-14.9%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: ZSAN is unprofitable, and losses have increased over the past 5 years at a rate of -14.9% per year.

Accelerating Growth: Unable to compare ZSAN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ZSAN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (28.2%).


Return on Equity

High ROE: ZSAN has a negative Return on Equity (-195.2%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: ZSAN is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: ZSAN is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Zosano Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: ZSAN's short term assets ($18.7M) exceeds its short term liabilities ($15.3M)

Long Term Liabilities: ZSAN's short term assets (18.7M) exceeds its long term liabilities (11.5M)


Debt to Equity History and Analysis

Debt Level: ZSAN is debt free.

Reducing Debt: ZSAN currently has no debt however we can't compare to 5 years ago as we have no data for that period.


Balance Sheet

Inventory Level: ZSAN has a high level of physical assets or inventory.

Debt Coverage by Assets: ZSAN's debt is not covered by short term assets (assets are -1.0544615577534E+16x debt).


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ZSAN has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if ZSAN has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Zosano Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage1.2%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate ZSAN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate ZSAN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if ZSAN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ZSAN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ZSAN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

  • Explore strong dividend paying companies in the Healthcare industry.

Management

What is the CEO of Zosano Pharma's salary, the management and board of directors tenure and is there insider trading?

2.3yrs

Average management tenure


CEO

John Walker (70yo)

2.4yrs

Tenure

US$1,970,982

Compensation

Mr. John P. Walker has been the Chief Executive Officer and President at Zosano Pharma Corporation since August 09, 2017 and served as its Interim Chief Executive Officer from May 9, 2017 to August 09, 201 ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether John's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

2.3yrs

Average Tenure

57yo

Average Age

Experienced Management: ZSAN's management team is considered experienced (2.3 years average tenure).


Board Age and Tenure

2.7yrs

Average Tenure

62yo

Average Age

Experienced Board: ZSAN's board of directors are not considered experienced ( 2.7 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUS$350,00018 Apr 19
John Walker
EntityIndividual
Role
Chief Executive Officer
Chairman
Shares100,000
Max PriceUS$3.50

Ownership Breakdown


Management Team

  • Don Kellerman (64yo)

    Vice President of Clinical Development & Medical Affairs

    • Tenure: 4.3yrs
    • Compensation: US$794.98k
  • Dushyant Pathak (57yo)

    Senior Vice President of Business Development

    • Tenure: 0.08yrs
  • John Walker (70yo)

    Chairman

    • Tenure: 2.4yrs
    • Compensation: US$1.97m
  • Hayley Lewis (43yo)

    Senior Vice President of Operations

    • Tenure: 2.3yrs
    • Compensation: US$781.73k
  • Greg Kitchener (48yo)

    Chief Financial Officer

    • Tenure: 1yrs
  • Jeffrey Quillen

    Secretary

    • Tenure: 0yrs

Board Members

  • Kenneth Greathouse (66yo)

    Independent Director

    • Tenure: 2yrs
    • Compensation: US$154.18k
  • Lind Grais (63yo)

    Independent Director

    • Tenure: 0.8yrs
  • Steve Elms (56yo)

    Independent Director

    • Tenure: 1.4yrs
    • Compensation: US$120.27k
  • Kleanthis G. Xanthopoulos (61yo)

    Independent Director

    • Tenure: 6.5yrs
    • Compensation: US$157.01k
  • Jay Hagan (50yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: US$160.01k
  • John Walker (70yo)

    Chairman

    • Tenure: 2.4yrs
    • Compensation: US$1.97m

Company Information

Zosano Pharma Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zosano Pharma Corporation
  • Ticker: ZSAN
  • Exchange: NasdaqCM
  • Founded: 2006
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$33.851m
  • Shares outstanding: 17.72m
  • Website: https://www.zosanopharma.com

Number of Employees


Location

  • Zosano Pharma Corporation
  • 34790 Ardentech Court
  • Fremont
  • California
  • 94555
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
ZSANNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDJan 2015
0ZPNDB (Deutsche Boerse AG)YesCommon StockDEEURJan 2015

Biography

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics to patients suffering from migraine using its Adhesive Dermally-Applied Microarray technology. Its l ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/17 00:30
End of Day Share Price2019/10/16 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.